STAT+: The next step of site-neutral, and a fiery PBM hearing

STAT PlusNewsletterHealth Care Inc. Newsletter The next step of site-neutral, and a fiery PBM hearing You’re reading STAT’s Health Care Inc. newsletter Manage alerts for this article Email this article Share this article By Bob HermanJuly 20, 2026 Business of Health Care Reporter Bob Herman[email protected]Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Hello, everyone! I’ve seen upwards of 50,000 public comments on proposed health care regulations, but the 200,000 comments (!) on the SEC’s proposal to eliminate quarterly financial reports is jaw-dropping. Yes, a lot of them seem like automated templates from interest groups, but still. Some poor soul has to sift through them. I’d like to see you try to send 200,000 comments here (please don’t): [email protected].Advertisement Site-Neutral Milk Hotel The most consequential policy in Medicare’s recent outpatient rule is the cuts to drugs that hospitals get under the 340B discount program. But the Centers for Medicare and Medicaid Services subtly doubled down on another major policy that hospitals loathe. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In CMS, drug development, Drug prices, government agencies, health care costs, Health insurance, hospitals, insurance, legal, Medicare, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Bob Herman Business of Health Care Reporter Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout July 17, 2026 STAT Plus: The end for GSK’s chronic cough treatment Business July 16, 2026 STAT Plus: GOP blocks effort to end Medicare test of AI prior authorization Advertisement Insurance July 16, 2026 STAT Plus: Despite earnings celebration, UnitedHealth signals more financial pain for employers The Readout July 16, 2026 STAT Plus: FDA approves Merck’s oral PCSK9 drug, a first Insurance July 15, 2026 STAT Plus: Elevance plots a Medicaid retreat as costs remain high Subscriber Picks